Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Bacterial pneumonia vaccines and childhood pneumonia: are we winning, refining, or redefining?

Stephen K Obaro, Shabir A Madhi

Bacterial pneumonia is a substantial cause of childhood morbidity and mortality worldwide, but determination of pathogen-specific burden remains a challenge. In less developed settings, the WHO recommended guidelines are useful for initiating care, but are non-specific. Blood culture has low sensitivity, while radiological findings are non-specific and do not discriminate between viral and bacterial causes of pneumonia. In vaccine probe studies, efficacy is dependent on the specificity of the study outcome to detect pneumonia and the impact of the vaccine on the selected outcome, and may underestimate the true burden of bacterial pneumonia. The rising incidence of antibiotic resistance, emerging respiratory pathogens, potential replacement pneumococcal disease following widespread introduction of pneumococcal polysaccharide-protein conjugate vaccine, the limited specificity of chest radiography, and the poor sensitivity of blood culture are substantial obstacles to accurate surveillance. We provide an overview of the diagnostic challenges of bacterial pneumonia and highlight the need for refining the current diagnostic approach to ensure adequate epidemiological surveillance of childhood pneumonia and the success, or otherwise, of any immunisation strategies.

Introduction

The annual incidence of pneumonia in children younger than 5 years of age is 34–40 cases per 1000 in Europe and North America. In the developing world, the incidence is several fold higher. Although the definition of pneumonia varies widely, it is often used interchangeably with acute lower respiratory tract infection in less developed countries. Lower respiratory tract infections—an inclusive terminology for pneumonia (both typical and atypical), bronchitis, bronchiolitis, and severe acute respiratory syndrome—remains a global paediatric health problem. Worldwide, more than 2 million children die of pneumonia annually. In a recent review of child mortality from preventable causes, pneumonia ranked second, and is responsible for 21% of deaths in children under the age of 5 years in low-income countries, especially in Africa and Asia, where 70% of deaths occur. Aetiological studies, which have been done largely in developing countries, suggest that *Streptococcus pneumoniae* may be the most common bacterial cause of pneumonia worldwide (figure), but accurate estimates of pathogen-specific attributable disease burden have been elusive.

The clinical symptoms of community-acquired pneumonia in children have not been systematically studied. Children are often brought to medical attention with fever and difficulty breathing with or without cough. Tachypnoea accompanied by crackles on auscultation suggests a diagnosis of pneumonia, although crackles are often not heard in children, particularly when the child is dehydrated. Wheezing is often associated with viral or mycoplasma infections. The WHO developed a guideline that recommends tachypnoea as the main indicator for the clinical diagnosis of lower respiratory infection (respiratory rate >50 breaths/min in infants and >40 breaths/min in children 1 year or older). Although the presence of tachypnoea may be the best way to distinguish lower from upper respiratory infection, there are no uniform criteria for initiating patient work-up with, for example, a chest radiograph or blood culture. The WHO recommendation has been useful in most developing countries for initiating antibiotic treatment or hospitalisation. However, in more developed countries, where laboratory and radiological investigations are done generously, criteria for diagnosis have been less stringent. The absence of uniform and objective criteria for the diagnosis of pneumonia has implications for the determination of the true burden of childhood pneumonia.

The respiratory mucosa and pneumonia

Bacterial colonisation of the nasopharynx provides an important key to the burden of several respiratory pathogens and prevention. In healthy populations, host risk factors affect colonisation rates, with the highest carriage rates in toddlers who attend day-care centres. Independent determinants for nasopharyngeal colonisation are ethnicity, environmental features,
crowding, socioeconomic status, family size, income, smoking, and antibiotic use.\textsuperscript{13}

The population of colonising organisms is diverse; interactions are complex and dynamic, involving different bacterial species and serotypes.\textsuperscript{12,13} Competition among different bacteria and the same bacteria of different serotypes has been recognised. For instance, it is known that alpha-haemolytic streptococci inhibit colonisation by \textit{S pneumoniae}, \textit{Haemophilus influenzae}, \textit{Staphylococcus aureus}, \textit{Streptococcus pyogenes}, and \textit{Moraxella catarrhalis}.\textsuperscript{14,15} \textit{S pneumoniae} interferes with the growth of \textit{S aureus}, an effect that has been attributed to pneumococcal hydrogen peroxide.\textsuperscript{16} Thus advantage for colonisation can result from inhibition of one bacterial species either by selective antimicrobial inhibition or by vaccination. The potential clinical impact of this observation is yet to be fully established. However, two studies from the Netherlands and Israel have suggested, based on epidemiological evidence, that \textit{S pneumoniae} might compete with \textit{S aureus} in colonisation.\textsuperscript{14,17}

Using \textit{S pneumoniae} as a model of a typical respiratory pathogen, disease begins with colonisation of the mucosal epithelium of the nasopharynx followed by translocation either to the middle ear, the paranasal sinuses, the alveoli of the lungs, or the bloodstream.\textsuperscript{18} It is likely that mucosal antibody responses are important in preventing both colonisation and disease.\textsuperscript{19} Interestingly, serotypes 1 and 5, which commonly cause invasive disease in developing countries, have rarely been detected in the nasopharynx of healthy children during carriage studies. It is possible that colonisation by these strains is short-lived or perhaps invasion occurs very rapidly following acquisition.

Parenteral immunisation with various polysaccharide-protein conjugate vaccines elicits serum IgG and secretory IgA that can be detected in the saliva of infants\textsuperscript{20} and toddlers.\textsuperscript{21} Circulating polysaccharide-specific IgA-secreting cells were detected 1 week after vaccination with conjugate vaccine in toddlers,\textsuperscript{22} indicating that parenteral immunisation with conjugate vaccines restimulates mucosal B memory cells generated during previous pneumococcal colonisation. However, mucosal IgA responses following parenteral vaccination were usually low and only detected in a proportion of vaccinees. Prevention of acquisition of new \textit{S pneumoniae} after vaccination also depends on the concentration of circulating anti-capsular IgG.\textsuperscript{13,19} Therefore, mucosal immunisation strategies with conjugate vaccines may have particular advantages for enhancing mucosal responses with improved efficacy against mucosal infections.

Pneumococcal conjugate vaccines reduce nasopharyngeal carriage but, unlike \textit{H influenzae} type b (Hib), the multiplicity of pneumococcal serotypes allows for a more complex interaction. Reduction in carriage of vaccine serotypes has been associated with an increase in carriage of non-vaccine serotypes. These non-vaccine serotypes cause replacement disease in the middle ear\textsuperscript{23} and will likely cause disease in the contiguous respiratory mucosal surface. Following the introduction of the heptavalent conjugate vaccine in the USA, there has been at least a three-fold increase in the incidence of non-vaccine serotype invasive disease but so far, in absolute terms this represents only a fraction of the burden of disease prevented by vaccination.\textsuperscript{24,25} In the event that an increase in the prevalence of colonisation by non-vaccine pneumococcal serotypes among vaccinees results in non-bacteraemic pneumonia, this will remain undetected by blood culture as currently used.

\textbf{Bacteraemic and non-bacteraemic pneumonia}

Although blood culture offers an excellent opportunity for the aetiological diagnosis of bacterial pneumonia, it is only useful when pneumonia is associated with bacteraemia (ie, bacteraemic pneumonia). Nevertheless, pneumococcal bacteraemia may be occult and sometimes innocuous, since it clears spontaneously in most children without sequelae.\textsuperscript{26} The yield from blood culture in patients with pneumonia has ranged from 10% to 30%.\textsuperscript{27}

The sensitivity of blood cultures for diagnosing pneumonia is poor and although its benefit may be restricted to bacteraemic pneumonia, bacteraemic and non-bacteraemic pneumonia may indeed be two different clinical entities. Current evidence suggests that bacteraemic pneumococcal pneumonia may be a more severe disease than non-bacteraemic pneumonia that is diagnosed by serology.\textsuperscript{28} It is noteworthy that the current WHO definition of acute lower respiratory tract infection does not include fever, and blood culture is seldom done in individuals who are afebrile.

Furthermore, blood culture will underestimate the incidence of pneumonia caused by bacteria that are less likely to invade the bloodstream. For example, \textit{Moraxella osloensis}\textsuperscript{29} has been reported to cause clinical and radiological features reminiscent of pneumococcal disease, but because this bacterium seldom invades the bloodstream, its true prevalence can only be ascertained by a different diagnostic method.

Since bacteraemia is detectable by blood culture and constitutes an important step in the pathogenesis of invasive bacterial disease, this has been an attractive outcome measure for the evaluation of any bacterial vaccine that targets childhood pneumonia. The sensitivity of blood culture in detecting the burden of pneumonia prevented by vaccination may, however, be as low as 3% in HIV-uninfected children and 18% in HIV-infected children, as recently shown in a pneumococcal vaccine efficacy trial in South Africa.\textsuperscript{30}

In a recent study from Kenya,\textsuperscript{31} bacteraemia was responsible for at least one-third of deaths in children over 1 year of age. This observation has important implications for the evaluation of pneumococcal conjugate vaccines in low-income countries.
implications for health-care intervention in the region but may in fact have provided an underestimation of the true burden of bacteraemia, since blood cultures were obtained only in children who presented to the hospital. Further limitations of blood culture for the detection of bacteraemia demonstrated in this study included loss of sensitivity by almost one-third when the yield from 1 mL blood inoculum was compared with 3 mL inoculum. Recent antibiotic use also reduced bacterial yield by 62–73%. The poor sensitivity of blood culture for the diagnosis of bacteraemia and the low incidence of bacteraemic pneumonia, coupled with the infrequent practice of obtaining blood culture in children with pneumonia, makes it unlikely that “preventable bacteraemic pneumonia” would be an outcome that is readily ascertained by clinicians or appreciated by public-health policymakers.

A study from The Gambia evaluated clinical signs that predict a positive blood culture in children presenting with pneumonia. High temperature (>38°C), dehydration, nasal flaring, grunting, bronchial breath sounds, and diminished air entry were positive predictors for a positive blood culture. The pattern of positive and negative predictors for culture of S pneumoniae was not different from that seen for positive blood cultures overall. Clinical signs of pneumonia were stronger positive predictors for culture of S pneumoniae than for culture of other bacteria and a positive chest radiograph for pneumonia was also a positive predictor. Although the report did not provide descriptive details of positive chest radiographs, it suggests that it is possible to select for individuals who are likely to have a positive blood culture based on several clinical parameters.

All efficacy trials of bacterial conjugate vaccines to date, have reported efficacy against bacteraemia and/or meningoitis, the most common manifestations of invasive bacterial disease. Following licensure of Hib conjugate vaccines and its remarkable success in controlling invasive Hib disease, pneumococcal conjugate vaccines were developed using a similar technology. The first efficacy trial was done in the USA and the vaccine was licensed in February 2000. Klugman and colleagues added further optimism to the global control of invasive pneumococcal disease in children. In addition to showing efficacy against invasive pneumococcal disease in HIV-uninfected children, the vaccine also reduced invasive pneumococcal disease by 65% (95% CI 24–86%) in HIV-infected children. This finding is important since HIV-infected children constitute a group with a 40-fold greater risk of developing invasive pneumococcal disease than HIV-uninfected children and contribute more than two-thirds of all bacteraemic pneumococcal cases in children from some sub-Saharan African countries.

More recently, in The Gambia, the same nonvalent pneumococcal conjugate vaccine that was evaluated in South Africa demonstrated efficacy against vaccine serotypes (77%; 95% CI 51–90%) but was associated with an increase (65%; p>0.05) in disease caused by non-vaccine serotypes. However, the absolute reduction in invasive pneumococcal disease (per 1000 child-years) due to the prevention of disease from vaccine serotypes was 1–9, compared with an increase of only 0–4 cases of invasive pneumococcal disease due to non-vaccine serotypes (hence a net prevention of 1·5 episodes of invasive pneumococcal disease per 1000 child-years). A similar increase in the incidence of disease caused by non-vaccine serotypes was observed in HIV-uninfected children in South Africa in whom a 75% (p=0·38) increase in invasive pneumococcal disease due to non-vaccine serotype diseases was observed. Whether the distribution of pneumococcal serotypes that cause bacteraemic pneumonia differ substantially from those that cause non-bacteraemic pneumonia is not known. However, should the incidence of non-bacteraemic pneumonia caused by non-vaccine serotypes increase, as has been the case for otitis media, current diagnostic methods would be inadequate for detecting this change.

Lung aspirate

Diagnostic lung tap, a procedure described over a century ago, may provide valuable information for the aetiology of non-bacteraemic pneumonia. Since the original description, the procedure has undergone several modifications but in many respects it is similar to a spinal tap. It is safer than is generally believed and does not involve general anaesthesia, as does bronchoalveolar lavage. Furthermore, pneumothorax resulting from lung tap is asymptomatic in most cases and resolves spontaneously. In a recent review of 59 studies, a bacterial aetiological diagnosis was obtained with a lung tap in over 50% of cases.

Some aetiological studies of pneumonia in which lung aspirates have been done suggest that the aetiology of pneumonia is sometimes polymicrobial; bacterial isolates obtained from blood culture may be discrepant from isolates obtained from lung or pleural aspirates. In a study of the aetiology of pneumonia in children from The Gambia, 100 children were investigated with blood culture and culture of lung and pleural aspirates. In 44 children, one species of bacterium was isolated from blood (six cases), lung culture (30 cases), or both (eight cases), while in eight children two species were isolated from lung or pleural aspirate, thus indicating that blood culture isolate may not always reflect the offending pathogen in the lung. In the group of children with lobar pneumonia or empyema, blood culture alone yielded a bacterial pathogen in 18 cases, while the addition of percutaneous lung aspirate or pleural aspiration increased the yield to 52 cases. In studies of lung aspirates, conventional bacterial culture techniques have been done to determine the aetiology of pneumonia. Although this technique has been
revealing, the yield may be considerably enhanced by molecular methods such as nucleic acid amplification techniques. In addition, since aspirates are done only on lung consolidation that is adjacent to the chest wall, the true burden of pneumonia prevented by vaccination using lung aspirates will be underestimated. Further, alveolar consolidation on chest radiographs may only detect 37% of the pneumonia that is otherwise preventable by vaccination.26

Data from lung aspiration studies need to be interpreted within context and their limitations appreciated. Although lung aspirates provide substantially more information regarding the aetiology of pneumonia compared with blood culture, they do not provide complete data on the true burden of non-bacteraemic pneumonia. The types of pneumonia that are accessible to lung aspiration may not be representative of the spectrum of pneumonia cases that present clinically. Reports of data from lung aspirate have been limited to pneumonia that present with large dense peripheral consolidations, predominantly on the right. Thus data from lung aspirate studies cannot be assumed to apply to the aetiological distribution of pneumonia with central interstitial infiltrates. The data from lung aspirate studies to date have also been limited because most bacterial isolates were not typed.

Radiology

Radiological findings are commonly accepted as the gold standard for defining pneumonia, although the different definitions have not been formally validated. In addition, considerable inter-observer and intra-observer variability in the interpretation of chest films has been reported.27 The value of routine chest radiographs in uncomplicated clinical pneumonia is controversial. Nevertheless, obtaining a chest radiograph for suspected cases of pneumonia is virtually standard practice in affluent countries. A broad spectrum of overlapping radiological findings has been observed in viral and bacterial pneumonia, although confluent opacities and alveolar infiltrates have been widely attributed to bacterial origin. Several studies have attempted to standardise the interpretation of chest radiographs in childhood pneumonia.28-30

The first report of radiological findings from a bacterial pneumonia vaccine trial in children was from The Gambia.31 In this study, Hib conjugate vaccine had an efficacy of 4% against WHO clinical pneumonia, 21% for radiological pneumonia, and 100% efficacy for Hib pneumonia confirmed by lung tap. This observation generated a lot of interest because other bacterial pneumonia vaccine studies were planned and standardisation of chest radiographs for vaccine efficacy studies was pursued. An effort to standardise the interpretation of chest radiographs, specifically for the purpose of evaluating the impact of vaccines on pneumonia, was initiated by the WHO. In 1998, a group of paediatricians and radiologists was set up to develop a consensus.32 Briefly, inter-observer variability in categorising chest radiographic images was measured by comparing the readings of 20 radiologists and clinicians against a reference set of 222 radiographic films. Intra-observer variability was measured by comparing the initial readings of a randomly chosen subset of 100 radiographs with repeat readings made 1–4 weeks later. The standardised definitions improved agreement substantially among members of the group for the identification of radiological pneumonia. Although the report provides a valuable guideline and an excellent tool for the evaluation of radiological pneumonia as an outcome measure in paediatric bacterial pneumonia vaccine efficacy trials or for epidemiological studies, unanswered questions remain. The definition of alveolar consolidation as proposed by the group needs to be formally evaluated to establish its correlation with bacterial pneumonia. Radiological pneumonia as proposed by the group is unlikely to be of use in the clinical setting where radiographs are evaluated in the context of clinical presentation and the indications for obtaining a chest radiograph vary considerably.

Meta-analysis of data from two randomised controlled trials of pneumococcal conjugate vaccine done in the USA and in South Africa suggest that pneumococcal conjugate vaccine reduces the incidence of radiological pneumonia by 22% (95% CI 11–31%).33 More recent findings from The Gambia,34 a country that is much less developed and with less access to antibiotics outside of the study centres compared with that in South Africa35 and the USA,36 showed a 37% reduction in radiological pneumonia (95% CI 27–45%). Differences in case ascertainment, clinical practice, and time from onset of symptoms to presentation to a health-care facility may in part explain the difference in the point estimate efficacy for radiological pneumonia (table 1).

In a report from California,37 the treating physician made a clinical diagnosis of pneumonia, based on individual appraisal of a physical examination; the need for a chest radiograph was based on the physician’s assessment. Over 300 radiologists interpreted the radiographs, thus introducing considerable potential for inter-observer variability. The study from South Africa38 and The Gambia39 used the standards recommended by the WHO Trialist Group for the interpretation of chest radiographs.40 However, the clinical indication for obtaining a chest radiograph in the South African study was based on individual study-physician assessment and was not standardised. When case reduction in all lower respiratory tract infection episodes was used as a benchmark for measuring the sensitivity of a standardised study endpoint of radiological pneumonia prevented by vaccination in South African HIV-uninfected children, chest radiography detected 58.1% (95% CI 50.3–65.6%) of pneumococcal pneumonia that was prevented by vaccination.41 In The Gambia, the
sensitivity of chest radiograph-confirmed pneumonia in detecting the burden of pneumonia prevented by vaccination was 76.5% (95% CI 50.1–93.2%). The importance of modifying the current clinical definition of lower respiratory tract infections to improve specificity for pneumococcal pneumonia was corroborated by findings in South Africa when, on further analysis, exclusion of children with wheezing in the absence of chest radiograph-confirmed pneumonia provided the most sensitive measure of vaccine-preventable pneumonia. Using this refined definition of clinical pneumonia, the sensitivity of chest radiograph-confirmed pneumonia in diagnosing the burden of pneumococcal pneumonia preventable by vaccination was only 37.5% (95% CI 31.6–43.6%). Despite the differences in radiological pneumonia in The Gambia compared with that observed in South Africa and the USA, the overall reduction in lower respiratory tract infections was similar between all the studies (6–9%). Furthermore, although efficacy against radiological pneumonia was 20% (95% CI 2–35%) and 13% (95% CI –7 to 29%) in HIV-uninfected and HIV-infected children, respectively, in South Africa, the case reduction in the burden of pneumococcal pneumonia prevented in HIV-infected children (2573 cases per 1000 person-years) was 10.4 (95% CI 9.2–11.6) fold greater than in HIV-uninfected children (267 cases per 1000 child-years). In Chile, Hib conjugate vaccine reduced substantially the incidence of non-bacteraemic pneumonia, particularly the cases with alveolar consolidation and/or pleural effusion. However, a cluster-randomised efficacy trial of the Hib conjugate vaccine in Lombok, Indonesia showed that the vaccine did not prevent most pneumonia cases, including those with alveolar consolidation (vaccine efficacy –1.2%; p>0.05) using the WHO guidelines for chest radiograph interpretation. Despite this, the absolute burden of clinically diagnosed lower respiratory tract infection was reduced by 15.6 cases per 1000 child-years (p<0.05) compared with a reduction of only 1.1 per 1000 child-years in The Gambia study, although differences in case ascertainment between these studies do not allow for a direct comparison to be made. Nevertheless, the lower proportional reduction in chest radiograph-confirmed pneumonia in Indonesia may reflect the predominance of pneumonia caused by other bacteria in this population. Other possible explanations for the differing results from Indonesia compared with other studies may include differences in case ascertainment and other local clinical practices that may have impacted on the specificity of chest radiographs for being used as a surrogate marker of “bacterial” pneumonia for evaluating vaccine efficacy.

There have also been two case-control studies that were done in Brazil and Colombia evaluating the effectiveness of Hib conjugate vaccine in preventing chest radiograph-confirmed pneumonia. The point estimate of reduction in radiograph-confirmed pneumonia in these studies, especially that in Colombia (vaccine effectiveness 55%; 95% CI 7–78%), was greater than that reported from The Gambia and Chile. However, inherent problems of case-control studies include the fact that unvaccinated children may have other medical and socioeconomic factors that may predispose them to developing pneumonia, which would bias the estimate of vaccine effectiveness against pneumonia upward. In addition, differences in the surveillance systems and criteria used for initiating investigation for pneumonia may also have affected the specificity of the chest radiographs in the individual studies for diagnosing “bacterial” pneumonia, which would also have biased the measured effectiveness upward. As an example, in the study from Colombia, chest radiographs were only done in children with clinical or laboratory suspicion of “bacterial” pneumonia, compared with the Gambian study where 69.7% of children referred to a health centre with clinical symptoms of lower respiratory tract infection had a chest radiograph. In Indonesia, the only study to have had active surveillance for lower respiratory tract infection outcome cases, 95.6% of children with a clinical diagnosis of lower respiratory tract infection had a chest radiograph done.

Differences in study design, case ascertainment, and procedures used for interpreting of chest radiograph makes direct comparison of the result between studies evaluating the usefulness of Hib conjugate vaccine problematic; nevertheless, it is of public-health importance that all of the studies, including that in Indonesia, confirmed that Hib conjugate vaccine reduces childhood morbidity associated with pneumonia. Detailed reports of the efficacy trial of pneumococcal conjugate vaccine and Hib conjugate vaccine trials at different sites with outcomes are summarised in table 1 and table 2, respectively.

**Acute phase reactants**

Various serological tests are available for the evaluation of acute lower respiratory tract infection in children but no specific test or panel of tests has consistently been useful in the differentiation of viral and bacterial pneumonia. The identification of markers of infection for discriminating between bacterial and viral pneumonia would have enormous potential for reducing the cost of unnecessary antibiotic prescriptions. Peripheral leucocytosis and/or raised erythrocyte sedimentation rates can corroborate bacterial pneumonia but neither reliably differentiates viral from bacterial pneumonia. Similarly, C-reactive protein (CRP), procalcitonin, and interleukin 6 levels are raised in bacterial pneumonia, but no reliable cut-off levels have been defined for clinical use. Considerable overlap in these values has made
interpretation of levels difficult. A hypotheses-generating study of data from the pneumococcal conjugate vaccine trial suggested that a CRP concentration of at least 120 mg/L or more and procalcitonin of at least 5 ng/mL (as adjunct markers of pneumococcal pneumonia) substantially improved the specificity of chest radiography in the diagnosis of pneumococcal pneumonia. However, this improvement in specificity was achieved by sacrificing the sensitivity (13·9%; 95% CI 9·9–18·6%) of this outcome in detecting the absolute burden of pneumococcal pneumonia that was prevented by vaccination.38,52

| Mean age at immunisation | California33 | South Africa30,38 | The Gambia35 |
|--------------------------|-------------|-----------------|-------------|
| First dose               | 8·6 weeks*  | 6·6 (SD 1·2) weeks | 10·7 weeks (range 8·4–15·5) |
| Second dose              | 17·3 weeks  | 11·2 (SD 2·5) weeks | 17·4 weeks (range 13·9–23·8) |
| Third dose               | 25·9 weeks  | 15·9 (SD 3·8) weeks | 24·2 weeks (range 19·4–32·2) |
| Booster                  | 65·4–78·4 weeks | No booster          | No booster            |
| Study population         | Urban American | Approximately 6·5% HIV infected | Rural African |
| Study vaccine            | Heptavalent PCV† | Nonavalent PCV‡     | Nonavalent PCV‡     |
| Study design             | Individual double blind randomised controlled trial | Individual double blind randomised controlled trial | Individual double blind randomised controlled trial |
| Definition/identification of LRTI/ pneumonia and diagnostic method | Attending physician clinical/radiological diagnosis of pneumonia | Overall study LRTI: study physician diagnosis based on clinical and/or radiological findings§ | Overall: cough <14 days and tachypnoea or lower chest wall indrawing |
| Efficacy (95% CI) against study-defined LRTI/pneumonia | ITT: 6·0% (–1·5 to 11) PP: 4·3% (–3·5 to 11·5) | Overall ITT: 9% (3–15) Overall PP: 31% (3–19) HIV negative ITT: 7% (–1 to 14) HIV negative PP: 9% (–1 to 18) HIV positive ITT: 15% (6–24) HIV positive PP: 11% (3–19) | ITT: 6% (1–13) PP: 7% (1–13) |
| Efficacy (95% CI) against severe pneumonia as defined by WHO criteria | – | Overall ITT: 12% (4–20) Overall PP: 17% (7–26) HIV negative ITT: 11% (1–20) HIV negative PP: 17% (4–27) HIV positive ITT: 17% (5–27) HIV positive PP: 23% (4–38) | PP: 12% (–9 to 29) |
| Overall incidence[1] in control group and VAR (in parentheses) for all pneumonia/LRTI | ITT: 45·8 (2·3) PP: 55·9 (2·5) Overall ITT: 35·7 (3·4) HIV negative ITT: 25·7 (1·7) HIV positive ITT: 167·2 (25·7) | PP: 248·5 (17) |
| Indication for chest radiograph | Attending physician discretion | Study-physician diagnosis of lower respiratory tract infection | Tachypnoea |
| Definition of radiological pneumonia | Attending radiologist/physician assessment of presence of consolidation, empyema or parenchymal infiltrate | Standardised reporting per WHO criteria | Standardised reporting per WHO criteria |
| Efficacy (95% CI) against radiologically defined pneumonia | ITT: 17·7% (4–8–28·9) PP: 20·5% (4–4–34·0) Overall ITT: 17% (4–28) Overall PP: 17% (2–20) HIV negative ITT: 20% (3–35) HIV positive ITT: 25% (4–40) HIV positive PP: 13% (–7 to 28) HIV positive PP: 9% (–15 to 27) | Overall PP: 37% (27–45) Overall ITT: 35% (26–43) Inpatient PP: 42% (30–53) Outpatient PP: 30% (15–43) |
| Incidence[2] in control and VAR (in parentheses) for radiologically defined pneumonia | ITT: 9·1 (1·8) PP: 11·0 (2·3) Overall ITT: 9·1 (1·6) HIV negative ITT: 4·9 (1·6) HIV positive ITT: 70·9 (9·1) | Overall ITT: 40·9 (14·9) Overall ITT: 37 (13) Inpatient PP: 20·7 (8·8) Outpatient PP: 20·2 (6·2) |
| Vaccine efficacy against blood and/or lung aspirate vaccine serotype disease in children with pneumonia¶ (95% CI) | ITT: 87·5% (p=0·004) Overall ITT: 61% (16–82) Overall PP: 50% (17–79) HIV negative ITT: 67% (15 to 93) HIV positive ITT: 75% (–124 to 97) HIV positive PP: 59% (1–83) HIV positive PP: 42% (–48 to 77) | PP: 70% (31–88)** |
| Incidence[3] in control and VAR (in parentheses) for vaccine serotype specific bacteraemic/lung aspirate plus pneumonia** | ITT: 0·2 (0·1B) Overall ITT: 0·5 (0·1) HIV negative ITT: 0·14 (0·09) HIV positive ITT: 5·8 (3·4) | PP: 2·0 (1·4) |

(continues)
Lung aspirates only done in The Gambia, and blood cultures done in all studies. **Includes lung aspirate and/or blood culture confirmed isolates. 11 (42·3%) of 26 cases in the placebo group and three (37·5%) of eight cases in vaccinees had positive lung aspirate. ††20 (44·4%) of 45 cases in controls and six (31·6%) of 19 cases in vaccinees had positive lung aspirate.

Includes serotypes 1 and 5 in addition to the seven serotypes included in the heptavalent PCV. §Subanalysis based on WHO clinical criteria of mild and severe/very severe pneumonia. ||Incidence per 1000 child-years.

extrapolation of vaccination schedule of 2, 4, 6 months and booster at 15–18 months. †Heptavalent PCV (pneumococcal polysaccharide protein conjugate vaccine) including serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F.

Table 1:

| Type of surveillance                  | California[33] | South Africa[34,35] | The Gambia[36] |
|--------------------------------------|---------------|---------------------|---------------|
| Vaccine efficacy against bloodstream and/or lung aspirate vaccine serotype disease in children with pneumonia (95% CI) | ITT: 87.5% (p<0.004) | Overall ITT: 44.5% (5-67) | PP: 58% (27-77)[††] |
| [continued]                          |               | Overall PP: 45% (2 to 70) |               |
|                                      |               | HIV negative ITT: 38% (91 to 80) |               |
|                                      |               | HIV negative PP: 40% (151 to 88) |               |
|                                      |               | HIV positive ITT: 45% (1-79) |               |
|                                      |               | HIV positive PP: 46% (6-72) |               |
| Incidence|| in control and VAR (in parentheses) for any pneumococcal serotype bacteraemic/lung aspirate | ITT: 0.25 (0.23) | Overall ITT: 0.05 (0.37) | PP: 3.5 (2.0) |
|                                      |               | HIV negative ITT: 0.19 (0.07) |               |
|                                      |               | HIV positive ITT: 10.7 (4.8) |               |
| Type of surveillance                  | Passive physician-care centred on inpatient; emergency room or outpatient cases | Passive surveillance of hospitalised patients | Passive outpatient and hospitalised surveillance at study hospital/health centre; subsequent addition of active community clinic surveillance with referral of cases to study centre |
|                                      |               | Passive ITT: 6.5 (1.3) |               |
|                                      |               | Passive PP: 15% (8-26) |               |
|                                      |               | Overall PP: 45% (16-66) |               |

– not reported; ITT=intent-to-treat analysis (ie, received at least one dose of vaccine); LRTI=lower respiratory tract infection; MnCV=meningococcal type C polysaccharide-protein conjugate vaccine; PCV=pneumococcal polysaccharide-protein conjugate vaccine; PP-per protocol analysis (ie, fully vaccinated children); VAR=vaccine attributable reduction per 1000 child-years. *Exact vaccination age of study cohort not reported. Based on extrapolation of vaccination schedule of 2, 4, 6 months and booster at 15–18 months. **Includes serotypes 1 and 5 in addition to the seven serotypes included in the heptavalent PCV. §Subanalysis based on WHO clinical criteria of mild and severe/very severe pneumonia. ††Incidence per 1000 child-years.

Although the combination of acute phase reactants and radiology for diagnosis is promising, its value warrants evaluation in prospective trials. The combination may be useful for minimising sample sizes required for evaluating vaccine efficacy (ie, through improved specificity of the study outcome measure); however, poor sensitivity would preclude its use in the measurement of the absolute burden of disease prevented by vaccination. Definition of markers that are useful for distinguishing between bacterial and viral pneumonia has been handicapped by the poor sensitivity of currently available tools for diagnosing bacterial pneumonia. This has recently been corroborated by using the pneumococcal conjugate vaccine as a probe in defining the minimal contribution of pneumococcal coinfection in children hospitalised with viral-associated pneumonia and determining the sensitivity of blood cultures for diagnosing pneumococcal pneumonia. In the absence of immunisation with pneumococcal conjugate vaccine, at least 30% of hospitalised viral-associated pneumonia was attributed to pneumococcal coinfections, albeit there being no difference in the prevalence of pneumococcal bacteriaemia (3%) between vaccine and placebo recipients.11 In a study of children attending daycare centres in Israel54 there was reduction in the incidence of presumed viral lower respiratory tract infections and a reduction in antibiotic use for lower respiratory tract infections.56

Defining disease burden with a “vaccine probe”

The concept of using a vaccine to define the burden of vaccine-preventable disease in a community is based on the concept of excess risk—ie, the risk difference—a standard parameter in studies of exposure to illness.51 This approach has been used previously with influenza vaccine in the evaluation of vaccine-preventable illness among pilgrims travelling to the Hajj from Pakistan.52 The difficulties associated with establishing a pathogen-specific burden of pneumonia and the lack of reproducible quantitative measures of pathogen-attributable risk make it difficult to justify the use of conjugate vaccines in many settings. However, there is little doubt that bacterial polysaccharide-protein conjugate vaccines have made a substantial impact in the battle against invasive bacterial diseases of childhood to date. The frustration associated with the lack of refined clinical and laboratory diagnostic tools to more quantitatively define the reduction in disease burden has prompted investigators to use the vaccine as a “probe” to define disease burden. The advantages and shortcomings of using this vaccine probe approach for the determination of disease burden was the subject of a recent review.53 Although the approach provides a powerful tool for the evaluation of vaccine efficacy against disease, disease reduction would only be proportional to vaccine efficacy against study-specified outcome measures, more appropriately referred to as vaccine-preventable disease. The proportion of disease prevented by vaccination will only be equal to disease burden when the vaccine has an efficacy of 100%. Since no such vaccine exists and, for licensed vaccines, efficacies vary in different populations, using this approach to define disease burden will underestimate the true disease burden. Although this strategy provides a powerful and unequivocal tool for the evaluation of reduction in all-cause morbidity and mortality, as demonstrated in The Gambia,54 the true burden of pneumococcal pneumonia remains undetermined because the vaccine impacts other forms of disease in addition to pneumonia.

Although the efficacy of protein conjugate bacterial polysaccharide vaccines has been very high for the
prevention of bacteraemia and meningitis, this has been less so for otitis media and pneumonia. Since it is known that the degree of infiltrates on chest radiograph does not correlate with clinical severity and radiological presentation of bacterial pneumonia is likely to be a continuum, the reduction in alveolar consolidation observed in several efficacy studies is likely to represent only a fraction of the total burden of pneumococcal pneumonia. Additional data on the impact of vaccination on pneumococcal pneumonia diagnosed by lung tap would certainly be informative, although this too would be somewhat limited, since the procedure is only done in selected cases.

### Pneumonia in the newborn

It is estimated that 10·8 million children die annually worldwide. Of these, 3·9 million deaths occur within the first 28 days of life.\(^{14}\) Using the current neonatal

| The Gambia\(^{43}\) | Chile\(^{59}\) | Lombok, Indonesia\(^{48}\) | Central Brazil\(^{49}\) | Colombia\(^{50}\) |
|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| **Mean age at immunisation** | | | | |
| First dose | 11 weeks (range 9·6–13·4) | 11 weeks\(^{1}\) | 2 months\(^{1}\) | 2 months |
| Second dose | 17·7 weeks (range 15·1–21·7) | 15 weeks | 4 months | 4 months |
| Third dose | 24·2 weeks (range 20·6–29·8) | 20 weeks | 6 months | 6 months |
| Booster | Nil | Nil | Nil | Nil |
| Study population | Rural | Rural | Rural | Urban |
| Study vaccine | PRP-T/placebo | PRP-T | PRP-T/placebo | PRP-CRM\(_{197}\) |
| **Study design** | | | | |
| Study paediatrician assessment of cases referred from health-care centres by nurses/doctors. | Retrospective review of discharge diagnosis of children from two of five administrative areas hospitalised at selected facilities. Only children that received at least two doses of DTP-Hib or DTP before episode of LRTI included. All cases were hospitalised. | Service provider recording of cases at primary health-care centres and study physician abstracting information for hospitalised children. | Cases investigated for pneumonia if cough and (1) tachypnoea or (2) chest wall indrawing and/or other signs of severe LRTI. Cases hospitalised irrespective of disease severity. | Cases children hospitalised with radiologically confirmed pneumonia. Controls: matched for age, sex, and socioeconomic class. Children investigated for pneumonia based on clinical or laboratory parameters suggestive of "bacterial" pneumonia. |
| **Overall LRTI/pneumonia cases included in the study** | | | | |
| | Retrospective demonstration project. Health-care centres randomised to either give DTP-PRP-T or DTP. Open-labelled | Cluster randomised double blind placebo controlled trial | | |
| **Efficacy (95% CI) against study-defined LRTI/ pneumonia** | | | | |
| ITT: 4·4% (–5·0 to 12·9) PP: 7·7% (–4·1 to 18·2) | At least one dose: 4·0%; p<0·05 | At least one dose: 4·8%; p<0·05 | For pneumonia defined by WHO criteria§ | For pneumonia defined by WHO criteria§ |
| **Overall incidence and VAR** | | | | |
| (in parentheses) in placebo group for all pneumonia/acute lower illness | | | | |
| ITT: 6·5% (6·9 to 18·1) PP: 9·4% (7·5 to 23·7) | At least one dose: 4·8%; p<0·05 | At least one dose: 4·3%; p<0·05 | For pneumonia defined by WHO criteria§ | For pneumonia defined by WHO criteria§ |
| **Incidence** and VAR in pneumonia (WHO criteria) in controls | | | | |
| (in parentheses) severe pneumonia (WHO criteria) | Retrospective review of discharge diagnosis of children from two of five administrative areas hospitalised at selected facilities. Only children that received at least two doses of DTP-Hib or DTP before episode of LRTI included. All cases were hospitalised. | Service provider recording of cases at primary health-care centres and study physician abstracting information for hospitalised children. | Cases investigated for pneumonia if cough and (1) tachypnoea or (2) chest wall indrawing and/or other signs of severe LRTI. Cases hospitalised irrespective of disease severity. | Cases children hospitalised with radiologically confirmed pneumonia. Controls: matched for age, sex, and socioeconomic class. Children investigated for pneumonia based on clinical or laboratory parameters suggestive of "bacterial" pneumonia. |
| **Proportion of children with LRTI/pneumonia in whom chest radiograph was done** | | | | |
| 69·7% (1269/1821) 58% reported to have had a chest radiograph | 59·5% (3171/5310B) | 59·5% (3171/5310B) | 59·5% (3171/5310B) | 59·5% (3171/5310B) |
| **Definition of radiological pneumonia** | | | | |
| Presence of “definite” alveolar consolidation. Chest radiographs interpreted by one of five study paediatricians. | Chest radiograph findings abstracted from reporting of attending radiologist or interpretation of radiologist blinded to child’s vaccination status. Categorisation into: alveolar consolidation, mixed alveolar-interstitial, interstitial with or without hyperinflation. | Used WHO guidelines for standardised reporting** | Used WHO guidelines for standardised reporting** | Chest radiographs read by a radiologist or respiratory physician. |

(continues)
Table 2: Efficacy/effectiveness studies on H influenzae type b conjugate vaccine against pneumonia in children

| Efficacy (95% CI) against radiologically defined pneumonia | The Gambia\(^{43}\) | Chile\(^{40}\) | Lombok, Indonesia\(^{41}\) | Central Brazil\(^{47}\) | Colombia\(^{48}\) |
|----------------------------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Received at least one dose of HibCV: 21.1% (4.6–34.9) | Considered vaccinated if received at least two doses of DTP or DTP-HibCV: 22.1% (-7.0 to 43.1)††† | At least one dose of HibCV: -4.9% (p=0.05) All three doses of HibCV: -12% (p=0.5) | Considered vaccinated if received at least two doses in infancy or one dose between 1–2 years of age: 31% (-9.0 to 57.0; p=0.21) | Received one dose: 47% (27.2; p=0.046) Received two doses: 52% (3.6; p=0.04) Received three doses: 55% (7.7; p=0.031) | |
| Received three doses of HibCV: 22.4% (19.3–36.8) | | | | |
| Incidence\(\text{\textdagger}\) in control and VAR (in parentheses) for radiologically defined pneumonia | 3.16 (0.79) | 5.0 (1.1) | At least one dose: 8.9 (-0.4; 95% CI -1.9 to 0.99) | NA | NA |
| Vaccine efficacy (95% CI) against bloodstream and/or lung aspirate disease in children with pneumonia | 87% (41.99) | 80% (p=0.039) | | | |
| Type of surveillance for outcome cases | Passive surveillance at health-care centres, followed by screening by health-care workers and subsequent referral of children with suspected Hib disease to study physicians | Retrospective review of selected hospital databases | Surveillance at primary health-care facilities and hospitals by attending health-care workers who submitted lists of patients with pneumonia (including mild and severe cases) or meningitis and clinical information. Also, data abstraction undertaken at hospitals for hospitalised cases | Cases identified at ambulatory clinics and hospitalised irrespective of clinical severity | Children presenting to hospital with physician clinical or laboratory suspicion of “bacterial” pneumonia. |

\(\text{\textdagger}\) Efficacy/effectiveness studies on Table 2.

–Not reported; DTP=diphtheria-tetanus-pertussis; Hib=Hemophilus influenzae type b; HibCV=Hemophilus influenzae type b conjugate vaccine; ITT=intent-to-treat; LRTI=lower respiratory tract infection; NA=not applicable; PP-per protocol; PRP-OMP, \_\_=diphtheria mutant toxoid carrier related molecule-polysaccharide ribitol; PRP-T-polysaccharide ribitol phosphate tetanus toxoid conjugate; VAR=vaccine attributable reduction per 1000 child-years.

\(\text{\textdagger\textdagger}\) Estimated ages based on scheduled dates of vaccination as part of routine recommended immunisation time points. All children under 2 years of age were eligible for inclusion; however, 95.7% of children enrolled were under 6 months of age at time of first vaccination. Children could have received one to three doses of study vaccine depending on how many doses of DTP had already been received by the time of randomisation. *Recommended schedule of 2, 4, and 6 months of age or a single dose between 1–2 years of age, if vaccination was incomplete (0–2 doses) during infancy. §Defined as presence of lower chest wall-indrawing. || Incidence rate per 1000 child-years. ¶Based on incidence rates (per 1000 child-years) calculated as per reference 48. **WHO recommended guidelines for chest radiograph interpretation in vaccine trials. ††Using a modified definition that was more sensitive for diagnosing “bacterial” pneumonia—i.e., consolidation, effusion, bronchial breathing, or ESR >40 mm/h—vaccine efficacy was calculated to be 26% (95% CI 7–44) with an incidence rate of 97/1000 child-years in control group, with a VAR of 2.5 per 1000 child-years. Importantly, children with mixed interstitial-alveolar consolidation were excluded as outcome cases for “radiologically confirmed pneumonia”, by contrast with the studies from The Gambia and Indonesia.

Table 2: Efficacy/effectiveness studies on H influenzae type b conjugate vaccine against pneumonia in children

mortality estimates and limited autopsy data reported in the literature, a recent review suggests that pneumonia may be responsible for between 750,000 and 1.2 million deaths and an unknown number of stillbirths each year worldwide.\(^{39}\) The greatest risk of death from pneumonia likely occurs during the neonatal period, at least in developing countries. In India, more than half of all child deaths from pneumonia occurred in neonates.\(^{46}\)

The aetiology and epidemiology of neonatal pneumonia is more complex than in infancy and childhood, and the aetiological spectrum is more diverse. In general, early onset disease (onset within the first week of life) occurs from bacterial infection of the amniotic fluid or colonisation of the maternal genital tract. Gram-negative bacteria are the predominant pathogens during the first week of life and Gram-positive bacteria thereafter. Intrauterine pneumonia is a component of early onset disease and may result in stillbirth. There have been conflicting reports on the incidence of neonatal group B streptococcal infections in developing and developed countries. A study of the aetiology of serious bacterial infections in young infants in several developing countries suggest that group B streptococcus was uncommon.\(^{61}\) This study recruited infants from an outpatient setting and would have missed out on the substantial burden of early onset disease. This report contrasts with recent observation from Kenya.\(^{62}\)

Clinical and aetiological diagnosis is even more challenging, since neonatal pneumonia often presents as neonatal sepsis and signs are ill-defined. A clinical distinction between early onset pneumonia and hyaline membrane disease is virtually impossible because of the similarity in radiological findings in these conditions. Blood culture yield is likely to be lower, given the smaller volume of blood specimen that is often available for culture. In one study from Brazil of 318 neonates who presented with respiratory distress within the first 72 hours of life, bacterial infection was proven by culture in 31 (9.7%) and 62 (19.5%) had radiographic changes suggestive of pneumonia.\(^{63}\) There are few aetiological studies of neonatal pneumonia that used lung tap for diagnosis. Two of these studies from India reported bacterial culture or bacterial antigen studies of lung aspirate and suggest that Escherichia coli and S pneumoniae are important causes of neonatal pneumonia.\(^{64,65}\)
Although substantial progress has been made with the development of polysaccharide-protein conjugate vaccines for most of the common bacterial pathogens of acute respiratory infections, there are other pathogens for which vaccines using similar technology are either in development or in early clinical trials—e.g., group B streptococcus. For several diseases with substantial pathogen-specific burden during early infancy (e.g., group B streptococcal disease, pneumococcal disease), it may be possible to offer protection to the newborn infant that could last through the first few months of life by offering vaccination to the mothers during pregnancy. Several studies have demonstrated the safety and immunogenicity of polyvalent pneumococcal polysaccharide vaccine administered during the second or third trimester of pregnancy, and more recently with a conjugate group B streptococcal vaccine. Immunisation with pneumococcal polysaccharide vaccines has been shown to be safe and immunogenic when administered in late pregnancy and functional serotype-specific antibodies have been detected in breast milk several months after delivery. Provided efficacy can be demonstrated, immunising mothers during pregnancy could offer the potential benefit of protection from pneumococcal disease for the mother and for the infant and protection from more pneumococcal serotypes than is currently available in the licensed heptavalent pneumococcal conjugate vaccine during the first several months of life. In addition, for such infants it may be possible to achieve adequate immune protection with the use of fewer doses of the conjugate vaccine later in infancy. Overall, given the complexity of the pathogenesis and broad spectrum of aetiological agents, control of neonatal pneumonia would involve other general supportive health-care interventions in addition to immunisation of women before or during pregnancy.

Conclusions

Substantial progress has been made in the control of bacterial pneumonia with the development of bacterial polysaccharide-protein conjugate vaccines for two major respiratory pathogens of childhood pneumonia, Hib and S pneumoniae. With these vaccines, pneumonia caused by these pathogens has been well controlled in several (mostly developed) countries where the use of either or both of these vaccines has become routine. However, the vaccines remain out of reach of children in most developing countries where substantial global burden of disease, morbidity, and mortality occur. Although the Global Alliance for Vaccine Initiative has been instrumental in making Hib conjugate vaccines available to some developing countries, lack of pathogen-specific pneumonia burden data remains a major obstacle to convincing health policy planners and political leaders of the need for such vaccines in developing countries. Even in some affluent countries, the perceived burden of disease has not provided economic justification for routine use of some of these vaccines. Although vaccine probe studies have been very informative, they are expensive, experimental, and at best only provide estimates of vaccine-preventable study-specific disease outcome. The development of better tools to determine the microbiological diagnosis of pneumonia is critical for the demonstration of disease burden. Such tools are vital for indicating both the need for vaccines and for monitoring the epidemiology of pneumonia thereafter. While the true burden of pneumonia remains unknown because of diagnostic difficulties, these vaccines provide minimum attributable rate reductions. Although the data may be incomplete because of diagnostic imprecision, the challenge is not when the data will be complete but when it is sufficient for initiating public-health decisions.

Conflicts of interest

The authors have participated in the evaluation of safety, immunogenicity and efficacy trials of Haemophilus influenzae type b and pneumococcal conjugate vaccines, both of which were sponsored at least in part by Wyeth Vaccines and Pediatrics or Sanofi-Aventis. The authors have also acted as consultants for Wyeth. In addition, SAM has had salary support and research grant funding from Wyeth Vaccines and Pediatrics during a phase 3 study on pneumococcal conjugate vaccine, and has been a temporary advisor to GlaxoSmithKline and Sanofi-Aventis.

Acknowledgments

We thank P Dennehry and E Wald for critical review of earlier versions of this manuscript.
51 Moulin F, Raymond J, Lorrot M, et al. Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch Dis Child 2001; 86: 332–36.

52 Madhi SA, Heera JR, Kuvwanda I, Klugman KP. Use of procalcitonin and C-reactive protein to evaluate vaccine efficacy against pneumococcal disease. PLoS Med 2005; 2: 147–51.

53 Madhi SA, Klugman KP. Vaccine Trialist Group. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004; 10: 811–13.

54 Dagan R, Suchler-Cohen M, Zamir O, Janco J, Givon-Lavi N, Fraser D. Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. Pediatr Infect Dis J 2001; 20: 951–58.

55 Hennekens CH, Buring JE. Measures of disease frequency. In: Mayrent SL, ed. Epidemiology in medicine. Boston, MA: Little Brown, 1987: 90–91.

56 Qureshi H, Gessner BD, Leboulleux D, Hasan H, Alam SE, Hennekens CH, Buring JE. Measures of disease frequency. In: Mayrent SL, ed. Epidemiology in medicine. Boston, MA: Little Brown, 1987: 90–91.

57 Mulholland K. Use of vaccine trials to estimate burden of disease. J Health Popul Nutr 2004; 3: 257–67.

58 Black RE, Moris SS, Bryce J. Where and why are 10 million children dying every year? Lancet 2003; 361: 2226–34.

59 Duke T. Neonatal pneumonia in developing countries. Arch Dis Child Fetal Neonatal Ed 2005; 90: F211–19.

60 Bang AT, Bang RA, Tale O, et al. Reduction in pneumonia mortality and total childhood mortality by means of community-based intervention trial in Gadchirali, India. Lancet 1993; 336: 201–06.

61 English M, Ngama M, Musumba C, et al. Causes and outcome of young infant admissions to a Kenyan district hospital. Arch Dis Child 2003; 88: 438–43.

62 English M, Ngama M, Musumba C, et al. Causes and outcome of young infant admissions to a Kenyan district hospital. Arch Dis Child 2003; 88: 438–43.

63 Mussi-Pinhoata MM, Nobre RA, Martinez FE, et al. Early-onset bacterial infection in Brazilian neonates with respiratory distress: a hospital-based study. J Trop Pediatr 2004; 50: 6–11.

64 Shakunthala SK, Rao GM, Ummila S. Diagnostic lung puncture aspiration in acute pneumonia of newborn. Indian Pediatr 1978; 15: 39–44.

65 Misra S, Bhakoo ON, Ayyagiri A, et al. Clinical and bacterial profile of neonatal pneumonia. Indian J Med Res 1991; 93: 366–70.

66 Baker CJ, Paolletti I, Rench MA, Guttersen HK, Edwards MS, Kasper DL. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J Infect Dis 2004; 189: 1103–12.

67 Baker CJ, Rench MA, McIntosh P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 2003; 21: 3468–72.

68 O’Dempsey TJ, McArdle T, Ceeseay SJ, et al. Immunization with a pneumococcal capsular polysaccharide vaccine during pregnancy. Vaccine 1996; 14: 963–70.

69 Mulholland K, Suara RO, Siber G, et al. Maternal immunization with Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in The Gambia. JAMA 1996; 275: 1182–88.

70 Munoz FM, Englund JA, Cheesman CC, et al. Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation. Vaccine 2001; 20: 826–37.

71 Quiambao BP, Nohynek H, Kaybty H, et al. Maternal immunization with pneumococcal polysaccharide vaccine in the Philippines. Vaccine 2003; 21: 3451–54.

72 Santosham M, Englund JA, McIntosh P, et al. Safety and antibody persistence following Haemophilus influenzae type b conjugate or pneumococcal polysaccharide vaccines given before pregnancy in women of childbearing age and their infants. Pediatr Infect Dis J 2001; 20: 931–40.

73 Shahid NS, Steinhoff MC, Hoque SS, Begum T, Thompson C, Siber GR. Serum, breast milk, and infant antibody after maternal immunization with pneumococcal vaccine. Lancet 1995; 346: 1252–57.

74 Obaro SK, Deubzer HE, Newman VO, Adegbola RA, Greenwood BM, Henderson DC. Serotype-specific pneumococcal antibodies in breast milk of Gambian women immunized with a pneumococcal polysaccharide vaccine during pregnancy. Pediatr Infect Dis J 2004; 21: 1023–29.

75 Deubzer HE, Obaro SK, Newman VO, Adegbola RA, Greenwood BM, Henderson DC. Colostrum obtained from women vaccinated with pneumococcal vaccine during pregnancy inhibits epithelial adhesion of Streptococcus pneumoniae. J Infect Dis 2004; 190: 1758–61.